Wave Life Sciences Inc. (WVE)
WVE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/0001193125-26-073472-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | WVE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Singapore |
| IPO year | 2015 |
| SEC CIK | 0001631574 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $42.7M |
| Net income | -$204.4M |
| Operating income | -$215.4M |
| Net margin | -478.3% |
| Operating margin | -504.1% |
| Revenue growth | -60.5% |
| Cash | $602.1M |
| Total assets | $638.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 13.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-27 |
| Cash and burn | $197.3M cash; operating cash flow -$51.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 197,228,968 (2026-10-21); 167,181,784 a year earlier; 99,053,902 three years earlier. | Cover page 2026-10-21 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-11 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $82.6M, sold $15.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $13.2M | -$61.9M | -$60.1M | $197.3M | No debt tags | $70.9M | 10-Q 2026-10-27 |
| Q2 2026 2026-06-30 | $2.3M | -$69.4M | -$53.6M | $368.0M | No debt tags | $65.4M | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $38.2M | -$26.1M | -$59.6M | $544.6M | No debt tags | $71.8M | 10-Q 2026-04-28 |
| Q4 2025 2025-12-31 | $17.2M | -$53.2M | -$33.8M | $602.1M | No debt tags | $42.7M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $7.6M | -$53.9M | -$44.7M | $196.2M | No debt tags | Needs four quarters | 10-Q 2026-10-27 |
| Q2 2025 2025-06-30 | $8.7M | -$50.5M | -$46.0M | $208.5M | No debt tags | Needs four quarters | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $9.2M | -$46.9M | -$63.0M | $243.1M | No debt tags | Needs four quarters | 10-Q 2026-04-28 |
| Q4 2024 2024-12-31 | Not filed | $29.3M | -$43.6M | $302.1M | No debt tags | $108.3M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-08-10 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-10-27 |
| Latest current report | 8-K | 2026-10-27 |
| Latest proxy | DEF 14A | 2026-10-14 |
Source: SEC EDGAR submissions feed, 744 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.1% |
| 1 month | -0.3% |
| 3 months | -39.8% |
| Year to date | -81.6% |
| 1 year | -53.1% |
| From 52-week high | -85.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HELP | Helus Pharma Inc. | $7.67 | -13.53% | $560.4M |
| ACRS | Aclaris Therapeutics Inc. | $3.60 | -8.04% | $571.8M |
| EVO | Evotec SE | $1.56 | -1.27% | $555.0M |
| ZVRA | Zevra Therapeutics Inc. | $9.25 | +1.87% | $550.4M |
| CLYM | Climb Bio Inc. | $9.94 | -4.05% | $583.9M |
| AVBP | ArriVent BioPharma Inc. | $11.56 | -11.15% | $597.9M |
| INDP | Indaptus Therapeutics Inc. | $3.45 | +8.83% | $529.9M |
| GERN | Geron Corporation | $0.9419 | -2.60% | $606.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier